By Nigam Arora
215 Buyouts — A New Record of Success for Arora Members
Avidity Biosciences (RNA) has received a buyout offer from Novartis (NVS) for approximately $12B. RNA is the 215th Arora Portfolio company to be bought out.
This milestone demonstrates the strength of The Arora Report’s approach.
Neuromuscular Diseases
Avidity Biosciences is developing RNA-targeted therapies using its antibody-oligonucleotide conjugate platform to address serious neuromuscular diseases, including Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy.
Buyout Details
RNA is long from $42. The buyout offer is for $72 per share in cash, roughly a 46% premium to the closing price on Friday. The buyout price represents a 71% gain for members. This success highlights the power of identifying buyout targets early.
The deal is expected to close in the first half of 2026 and includes a spin out of Avidity’s early stage cardiology programs into a separate entity.
Billionaire And Hedge Fund Technique — Now Accessible To You
Buyouts are a core wealth building strategy used by sophisticated investors such as billionaires and hedge funds. The Arora Report delivers this same approach to individual investors with notable success.
Recent Arora Portfolio buyouts include:
• Hologic (HOLX): 290% gain, acquired by Blackstone and TPG
• Akero Therapeutics (AKRO): Premium acquisition by Novo Nordisk for $60 per share,
• Electronic Arts (EA): 913% gain with a cash buyout offer of $210 per share
The Arora Report’s record is better than firms charging upwards of $50,000 per year for buyout advice. With The Arora Report, you get so much more.
The results speak for themselves — substantial buyout returns delivered across changing market environments.
What To Do Now
RNA is trading at $70.05 as of this writing. Consider taking profits and exiting.
Why This Matters Going Forward
The ongoing wave of consolidation points to increasing opportunity for buyouts in:
- Biotechnology and life sciences
- Artificial intelligence and data infrastructure
- Lithium and critical minerals
- Space, defense, and high-tech manufacturing
By being positioned early and following a disciplined process, investors may continue to benefit from upcoming M&A catalysts. The RNA acquisition is a clear example of the potential ahead.
Start Your Free 30-Day Trial — Profit From the Next Buyout
New investors face uncertainty. Disciplined investors follow a proven framework. The Arora Report provides:
- Actionable signals in Real Time Feeds
- Buy zones that remove guesswork
- Strategies used by the most sophisticated investors
- Daily market guidance in the Morning Capsule
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 1% of the content from our paid services. …TO RECEIVE REMAINING 99%, INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES AND SIGNALS IN REAL TIME, TAKE A FREE
TRIAL TO PAID SERVICES.
The Arora Report is one of the only major global investment newsletters that does not employ a single salesperson—because it does not need to. While competitors rely on high-pressure sales tactics, The Arora Report grows purely through results, with satisfied members recommending it to their family and friends.
Join the service that investors trust the most and recommend to family and friends.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
